Market Place

Busiwire

Research and Markets: Public Sector Funding for Indonesia's Healthcare Remains Low, Estimated At Around US$4.4 Billion In 2008

Thursday May 14, 05:30 AM

Print This Story RSS

Research and Markets (http://www.researchandmarkets.com/research/0c1fd2/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Indonesia" report to their offering.
In November 2008, the Health Ministry introduced rules requiring drug companies to have production facilities in the country, in order to get licences to sell their products in Indonesia. The rules will affect 13 international companies that sell their products in Indonesia but do not have manufacturing facilities.
The economy is predicted to slow in 2009, expanding at just 3.5% compared to an estimated 6.1% in 2008 largely due to a lower demand for Indonesian exports. The stock market and the Indonesian rupiah took a beating in 2008. The government under president Bambang Susilo Yudhoyono faces the challenge of steadying its currency from further devaluation.
Public sector funding for healthcare is low, estimated at around US$4.4 billion in 2008 and the country continues to rely on international aid. Despite the present administration placing more emphasis on healthcare and funding, the insufficient number of health professionals and bureaucratic problems are hampering development.
Protection of intellectual property rights is generally regarded as inadequate in Indonesia and counterfeiting is also a major problem. Although the government has started to crackdown on distributors of counterfeit drugs, intellectual property protection for pharmaceuticals remains weak. The country remained on the US government's Watch List in 2008.
The domestic pharmaceutical manufacturing industry is strong and the country has become an attractive base for many multinational producers to operate. This is largely down to a cheap labour force and generally inexpensive production costs.
Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Key Topics Covered:
EXECUTIVE SUMMARY
Market Structure
Domestic Manufacturing
Local Manufacturers
Multinational Manufacturers
Exports
Pharmaceutical Regulatory Analysis
Pharmaceutical Regulation
Pricing & Reimbursement
Pharmaceutical Distribution
DIRECTORY
Methodology & Sources
List of Tables
Companies Mentioned:
Innogene Kalbiotech
Darya-Varia Group
PT Indofarma
Kalbe Farma
PT Kimia
PT Tempo Scan Pacific
PT Dexa Medica
PT Bio Farma
For more information visit http://www.researchandmarkets.com/research/0c1fd2/the_pharmaceutical.
Source: Espicom Business Intelligence Ltd

Contact:Research and MarketsLaura WoodSenior Managerpress@researchandmarkets.comFax 
      from USA: 646-607-1907Fax from rest of the world: +353-1-481-1716

Print This Story RSS

Next Article: Research and Markets: Structural Building Materials Market in Indonesia: Business Report 2009
Previous article: Research and Markets: Global Palm Oil Industry, Opportunities and Challenges - China, India and Indonesia Consume More than 80% of Palm Oil


Search:
Privacy Policy | Terms of Service | Help
Copyright © 2009 Yahoo! All rights reserved.
Yahoo!Xtra: A Yahoo!7/Telecom New Zealand Company.